December 11, 2012 Aeterna Zentaris: Final Phase 2 Data Demonstrate Perifosine and Sorafenib Combination Therapy Well Tolerated by Heavily Pretreated Lymphoma Patients

December 11, 2012 Aeterna Zentaris: Final Phase 2 Data Demonstrate Perifosine and Sorafenib Combination Therapy Well Tolerated by Heavily Pretreated Lymphoma Patients

[at noodls] – December 11, 2012 Aeterna Zentaris: Final Phase 2 Data Demonstrate Perifosine and Sorafenib Combination Therapy Well Tolerated by Heavily Pretreated Lymphoma Patients Promising clinical response activity … more

View todays social media effects on AEZS

View the latest stocks trending across Twitter. Click to view dashboard

See who AEterna is hiring next, click here to view

Share this post

Comments (0)